CoChat
Sign Up
Cited by 176Liver Disease Diagnosis and TreatmentBariatric Surgery and OutcomesLiver Disease and Transplantation

Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects

Open access
Laursen, Tea L, Hagemann, Christoffer A, Wei, Chunshan, Kazankov, Konstantin, Thomsen, Karen L, Knop, Filip K, Grønbæk, Henning·2019·World Journal of Hepatology
DOI 10.4254/wjh.v11.i2.138PMC PMC6393715
Open this paper in CoChat — free accountOpen PDF

Abstract

Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a significant liver disease, and it covers the disease spectrum from simple steatosis with a risk of development of non-alcoholic steatohepatitis (NASH) to fibrosis, subsequent cirrhosis, end-stage liver failure, and liver cancer with a potential need for liver transplantation. NAFLD and NASH are closely related to obesity, metabolic syndrome, and type 2 diabetes (T2D). The role of gut hormones, especially glucagon-like peptide 1 (GLP-1), is important in NAFLD. Bariatric surgery has the potential for inducing great weight loss and may improve the symptoms of metabolic syndrome and T2D. Recent data demonstrated significant effects of bariatric surgery on GLP-1 and other gut hormones and important lipid metabolic and inflammatory abnormalities in the pathophysiology of NAFLD. Therefore, bariatric surgery may reverse the pathological liver changes in NAFLD and NASH patients. In the present review, we describe NAFLD and NASH pathophysiology and the primary effects of bariatric surgery on metabolic pathways. We performed a systematic review of the beneficial and harmful effects and focused on changes in liver disease severity in NAFLD and NASH patients. The specific focus was liver histopathology as assessed by the invasive liver biopsy. Additionally, we reviewed several non-invasive methods used for the assessment of liver disease severity following bariatric surgery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4254/wjh.v11.i2.138

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Studies have shown that around 72-75% of patients showed diabetes resolution up to 2 years after bariatric surgery.

    “This might be due to the high remission rates of type II diabetes after bariatric surgery where studies have shown that around 72–75% showed diabetes resolution up to 2 years after surgery [66, 67, 68].”

    From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [66]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 86

  1. [1]Blachier M Leleu H Peck-Radosavljevic M Valla DC Roudot-Thoraval F The burden of liver disease in Europe: a review of available epidemiological data J Hepatol 2013 58 593 608 23419824
  2. [2]Chalasani N Younossi Z Lavine JE Diehl AM Brunt EM Cusi K Charlton M Sanyal AJ The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 2012 55 2005 2023 22488764
  3. [3]Vernon G Baranova A Younossi ZM Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults Aliment Pharmacol Ther 2011 34 274 285 21623852
  4. [4]Younossi ZM Stepanova M Afendy M Fang Y Younossi Y Mir H Srishord M Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008 Clin Gastroenterol Hepatol 2011 9 524 530.e1; quiz e60 21440669
  5. [5]Cortez-Pinto H Camilo ME Baptista A De Oliveira AG De Moura MC Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999 18 353 358 10634920
  6. [6]Prashanth M Ganesh HK Vima MV John M Bandgar T Joshi SR Shah SR Rathi PM Joshi AS Thakkar H Menon PS Shah NS Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus J Assoc Physicians India 2009 57 205 210 19588648
  7. [7]Pagano G Pacini G Musso G Gambino R Mecca F Depetris N Cassader M David E Cavallo-Perin P Rizzetto M Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association Hepatology 2002 35 367 372 11826410
  8. [8]Sanyal AJ Campbell-Sargent C Mirshahi F Rizzo WB Contos MJ Sterling RK Luketic VA Shiffman ML Clore JN Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities Gastroenterology 2001 120 1183 1192 11266382
  9. [9]Madsbad S Dirksen C Holst JJ Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery Lancet Diabetes Endocrinol 2014 2 152 164 24622719
  10. [10]Lassailly G Caiazzo R Buob D Pigeyre M Verkindt H Labreuche J Raverdy V Leteurtre E Dharancy S Louvet A Romon M Duhamel A Pattou F Mathurin P Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients Gastroenterology 2015 149 379 388; quiz e15-16 25917783
  11. [11]Maciejewski ML Arterburn DE Van Scoyoc L Smith VA Yancy WS Jr Weidenbacher HJ Livingston EH Olsen MK Bariatric Surgery and Long-term Durability of Weight Loss JAMA Surg 2016 151 1046 1055 27579793 PMC5112115
  12. [12]Brunt EM Wong VW Nobili V Day CP Sookoian S Maher JJ Bugianesi E Sirlin CB Neuschwander-Tetri BA Rinella ME Nonalcoholic fatty liver disease Nat Rev Dis Primers 2015 1 15080 27188459
  13. [13]Romeo S Kozlitina J Xing C Pertsemlidis A Cox D Pennacchio LA Boerwinkle E Cohen JC Hobbs HH Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Nat Genet 2008 40 1461 1465 18820647 PMC2597056
  14. [15]Pirola CJ Gianotti TF Burgueño AL Rey-Funes M Loidl CF Mallardi P Martino JS Castaño GO Sookoian S Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease Gut 2013 62 1356 1363 22879518
  15. [16]Sookoian S Rosselli MS Gemma C Burgueño AL Fernández Gianotti T Castaño GO Pirola CJ Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter Hepatology 2010 52 1992 2000 20890895
  16. [17]Donnelly KL Smith CI Schwarzenberg SJ Jessurun J Boldt MD Parks EJ Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease J Clin Invest 2005 115 1343 1351 15864352 PMC1087172
  17. [18]Lewis GF Carpentier A Adeli K Giacca A Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes Endocr Rev 2002 23 201 229 11943743
  18. [19]Cusi K Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis Clin Liver Dis 2009 13 545 563 19818304
  19. [20]Postic C Girard J Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice J Clin Invest 2008 118 829 838 18317565 PMC2254980
  20. [22]Kammoun HL Chabanon H Hainault I Luquet S Magnan C Koike T Ferré P Foufelle F GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice J Clin Invest 2009 119 1201 1215 19363290 PMC2673873
  21. [23]Jacome-Sosa MM Parks EJ Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans Curr Opin Lipidol 2014 25 213 220 24785962
  22. [24]Yamaguchi K Yang L McCall S Huang J Yu XX Pandey SK Bhanot S Monia BP Li YX Diehl AM Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis Hepatology 2007 45 1366 1374 17476695
  23. [26]Luedde T Kaplowitz N Schwabe RF Cell death and cell death responses in liver disease: mechanisms and clinical relevance Gastroenterology 2014 147 765 783.e4 25046161 PMC4531834
  24. [27]Feldstein AE Canbay A Angulo P Taniai M Burgart LJ Lindor KD Gores GJ Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis Gastroenterology 2003 125 437 443 12891546
  25. [28]Tosello-Trampont AC Landes SG Nguyen V Novobrantseva TI Hahn YS Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production J Biol Chem 2012 287 40161 40172 23066023 PMC3504730
  26. [29]Wehr A Baeck C Ulmer F Gassler N Hittatiya K Luedde T Neumann UP Trautwein C Tacke F Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury PLoS One 2014 9 e112327 25372401 PMC4221470
  27. [30]Seki E De Minicis S Osterreicher CH Kluwe J Osawa Y Brenner DA Schwabe RF TLR4 enhances TGF-beta signaling and hepatic fibrosis Nat Med 2007 13 1324 1332 17952090
  28. [31]Buchwald H Avidor Y Braunwald E Jensen MD Pories W Fahrbach K Schoelles K Bariatric surgery: a systematic review and meta-analysis JAMA 2004 292 1724 1737 15479938
  29. [32]Sjöström L Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery J Intern Med 2013 273 219 234 23163728
  30. [33]Schauer PR Bhatt DL Kirwan JP Wolski K Aminian A Brethauer SA Navaneethan SD Singh RP Pothier CE Nissen SE Kashyap SR STAMPEDE Investigators Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes N Engl J Med 2017 376 641 651 28199805 PMC5451258
  31. [35]Leonetti F Capoccia D Coccia F Casella G Baglio G Paradiso F Abbatini F Iossa A Soricelli E Basso N Obesity, type 2 diabetes mellitus, and other comorbidities: a prospective cohort study of laparoscopic sleeve gastrectomy vs medical treatment Arch Surg 2012 147 694 700 22508671
  32. [36]Ackerman NB Observations on the improvements in carbohydrate metabolism in diabetic and other morbidly obese patients after jejunoileal bypass Surg Gynecol Obstet 1981 152 581 586 7013122
  33. [37]Bojsen-Møller KN Dirksen C Jørgensen NB Jacobsen SH Serup AK Albers PH Hansen DL Worm D Naver L Kristiansen VB Wojtaszewski JF Kiens B Holst JJ Richter EA Madsbad S Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass Diabetes 2014 63 1725 1737 24241533
  34. [39]Jørgensen NB Dirksen C Bojsen-Møller KN Jacobsen SH Worm D Hansen DL Kristiansen VB Naver L Madsbad S Holst JJ Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes Diabetes 2013 62 3044 3052 23649520 PMC3749359
  35. [40]Romero F Nicolau J Flores L Casamitjana R Ibarzabal A Lacy A Vidal J Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects Surg Endosc 2012 26 2231 2239 22302537
  36. [41]Dirksen C Bojsen-Møller KN Jørgensen NB Jacobsen SH Kristiansen VB Naver LS Hansen DL Worm D Holst JJ Madsbad S Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass Diabetologia 2013 56 2679 2687 24048673
  37. [42]Falkén Y Hellström PM Holst JJ Näslund E Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides J Clin Endocrinol Metab 2011 96 2227 2235 21543426
  38. [43]Nguyen NQ Debreceni TL Bambrick JE Bellon M Wishart J Standfield S Rayner CK Horowitz M Rapid gastric and intestinal transit is a major determinant of changes in blood glucose, intestinal hormones, glucose absorption and postprandial symptoms after gastric bypass Obesity (Silver Spring) 2014 22 2003 2009 24829088
  39. [44]Melissas J Leventi A Klinaki I Perisinakis K Koukouraki S de Bree E Karkavitsas N Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study Ann Surg 2013 258 976 982 23160151
  40. [45]Kuhre RE Christiansen CB Saltiel MY Wewer Albrechtsen NJ Holst JJ On the relationship between glucose absorption and glucose-stimulated secretion of GLP-1, neurotensin, and PYY from different intestinal segments in the rat Physiol Rep 2017 5 PMC5727272 29199179
  41. [46]Jorsal T Rhee NA Pedersen J Wahlgren CD Mortensen B Jepsen SL Jelsing J Dalbøge LS Vilmann P Hassan H Hendel JW Poulsen SS Holst JJ Vilsbøll T Knop FK Enteroendocrine K and L cells in healthy and type 2 diabetic individuals Diabetologia 2018 61 284 294 28956082
  42. [47]Svegliati-Baroni G Saccomanno S Rychlicki C Agostinelli L De Minicis S Candelaresi C Faraci G Pacetti D Vivarelli M Nicolini D Garelli P Casini A Manco M Mingrone G Risaliti A Frega GN Benedetti A Gastaldelli A Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int 2011 31 1285 1297 21745271
  43. [48]Vetter ML Wadden TA Teff KL Khan ZF Carvajal R Ritter S Moore RH Chittams JL Iagnocco A Murayama K Korus G Williams NN Rickels MR GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification Diabetes 2015 64 434 446 25204975 PMC4392925
  44. [49]Steven S Hollingsworth KG Small PK Woodcock SA Pucci A Aribasala B Al-Mrabeh A Batterham RL Taylor R Calorie restriction and not glucagon-like peptide-1 explains the acute improvement in glucose control after gastric bypass in Type 2 diabetes Diabet Med 2016 33 1723 1731 27589584
  45. [50]Kotronen A Vehkavaara S Seppälä-Lindroos A Bergholm R Yki-Järvinen H Effect of liver fat on insulin clearance Am J Physiol Endocrinol Metab 2007 293 E1709 E1715 17895288
  46. [51]Jackness C Karmally W Febres G Conwell IM Ahmed L Bessler M McMahon DJ Korner J Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell Function in type 2 diabetic patients Diabetes 2013 62 3027 3032 23610060 PMC3749351
  47. [52]Jiménez A Mari A Casamitjana R Lacy A Ferrannini E Vidal J GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes Diabetes 2014 63 3372 3377 24848069
  48. [53]Salehi M Vella A McLaughlin T Patti ME Hypoglycemia After Gastric Bypass Surgery: Current Concepts and Controversies J Clin Endocrinol Metab 2018 103 2815 2826 30101281 PMC6692713
  49. [54]Dirksen C Eiken A Bojsen-Møller KN Svane MS Martinussen C Jørgensen NB Holst JJ Madsbad S No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3 Years After Gastric Bypass Surgery Obes Surg 2016 26 2263 2267 27138601
  50. [55]Salehi M Gastaldelli A D'Alessio DA Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass Gastroenterology 2014 146 669 680.e2 24315990 PMC3943944
  51. [57]Vilar-Gomez E Martinez-Perez Y Calzadilla-Bertot L Torres-Gonzalez A Gra-Oramas B Gonzalez-Fabian L Friedman SL Diago M Romero-Gomez M Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis Gastroenterology 2015 149 367 378.e5; quiz e14-15 25865049
  52. [58]Yousseif A Emmanuel J Karra E Millet Q Elkalaawy M Jenkinson AD Hashemi M Adamo M Finer N Fiennes AG Withers DJ Batterham RL Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans Obes Surg 2014 24 241 252 23996294 PMC3890046
  53. [59]Laurenius A Larsson I Bueter M Melanson KJ Bosaeus I Forslund HB Lönroth H Fändriks L Olbers T Changes in eating behaviour and meal pattern following Roux-en-Y gastric bypass Int J Obes (Lond) 2012 36 348 355 22124454
  54. [61]Svane MS Jørgensen NB Bojsen-Møller KN Dirksen C Nielsen S Kristiansen VB Toräng S Wewer Albrechtsen NJ Rehfeld JF Hartmann B Madsbad S Holst JJ Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery Int J Obes (Lond) 2016 40 1699 1706 27434221
  55. [62]Cummings DE Weigle DS Frayo RS Breen PA Ma MK Dellinger EP Purnell JQ Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery N Engl J Med 2002 346 1623 1630 12023994
  56. [63]Faraj M Havel PJ Phélis S Blank D Sniderman AD Cianflone K Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects J Clin Endocrinol Metab 2003 88 1594 1602 12679444
  57. [65]Palleja A Kashani A Allin KH Nielsen T Zhang C Li Y Brach T Liang S Feng Q Jørgensen NB Bojsen-Møller KN Dirksen C Burgdorf KS Holst JJ Madsbad S Wang J Pedersen O Hansen T Arumugam M Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota Genome Med 2016 8 67 27306058 PMC4908688
  58. [66]Klein S Mittendorfer B Eagon JC Patterson B Grant L Feirt N Seki E Brenner D Korenblat K McCrea J Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease Gastroenterology 2006 130 1564 1572 16697719
  59. [67]Viana EC Araujo-Dasilio KL Miguel GP Bressan J Lemos EM Moyses MR de Abreu GR de Azevedo JL Carvalho PS Passos-Bueno MR Errera FI Bissoli NS Gastric bypass and sleeve gastrectomy: the same impact on IL-6 and TNF-α. Prospective clinical trial Obes Surg 2013 23 1252 1261 23475776
  60. [68]Chavez-Tapia NC Tellez-Avila FI Barrientos-Gutierrez T Mendez-Sanchez N Lizardi-Cervera J Uribe M Bariatric surgery for non-alcoholic steatohepatitis in obese patients Cochrane Database Syst Rev 2010 1 CD007340 20091629 PMC7208314
  61. [69]Mummadi RR Kasturi KS Chennareddygari S Sood GK Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis Clin Gastroenterol Hepatol 2008 6 1396 1402 18986848
  62. [71]Stratopoulos C Papakonstantinou A Terzis I Spiliadi C Dimitriades G Komesidou V Kitsanta P Argyrakos T Hadjiyannakis E Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity Obes Surg 2005 15 1154 1160 16197789
  63. [72]Mathurin P Gonzalez F Kerdraon O Leteurtre E Arnalsteen L Hollebecque A Louvet A Dharancy S Cocq P Jany T Boitard J Deltenre P Romon M Pattou F The evolution of severe steatosis after bariatric surgery is related to insulin resistance Gastroenterology 2006 130 1617 1624 16697725
  64. [73]Mathurin P Hollebecque A Arnalsteen L Buob D Leteurtre E Caiazzo R Pigeyre M Verkindt H Dharancy S Louvet A Romon M Pattou F Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease Gastroenterology 2009 137 532 540 19409898
  65. [75]Taitano AA Markow M Finan JE Wheeler DE Gonzalvo JP Murr MM Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis J Gastrointest Surg 2015 19 429 436; discussion 436-437 25537957
  66. [80]Praveen Raj P Gomes RM Kumar S Senthilnathan P Karthikeyan P Shankar A Palanivelu C The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: "NASHOST" prospective observational trial Surg Obes Relat Dis 2015 11 1315 1322 26003897
  67. [81]Schneck AS Anty R Patouraux S Bonnafous S Rousseau D Lebeaupin C Bailly-Maitre B Sans A Tran A Gugenheim J Iannelli A Gual P Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis Front Physiol 2016 7 344 27594839 PMC4990543
  68. [82]Froylich D Corcelles R Daigle C Boules M Brethauer S Schauer P Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study Surg Obes Relat Dis 2016 12 127 131 26077701
  69. [84]Manco M Mosca A De Peppo F Caccamo R Cutrera R Giordano U De Stefanis C Alisi A Baumann U Silecchia G Nobili V The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis J Pediatr 2017 180 31 37.e2 27697327
  70. [85]Garg H Aggarwal S Shalimar Yadav R Datta Gupta S Agarwal L Agarwal S Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients Surg Obes Relat Dis 2018 14 81 91 29126863
  71. [86]Aguilar-Olivos NE Almeda-Valdes P Aguilar-Salinas CA Uribe M Méndez-Sánchez N The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome Metabolism 2016 65 1196 1207 26435078
  72. [87]Nickel F Tapking C Benner L Sollors J Billeter AT Kenngott HG Bokhary L Schmid M von Frankenberg M Fischer L Mueller S Müller-Stich BP Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up: BariScan Study Obes Surg 2018 28 1342 1350 29119336
  73. [90]Loy JJ Youn HA Schwack B Kurian M Ren Fielding C Fielding GA Improvement in nonalcoholic fatty liver disease and metabolic syndrome in adolescents undergoing bariatric surgery Surg Obes Relat Dis 2015 11 442 449 25820083
  74. [91]Simo KA McKillop IH McMillan MT Ahrens WA Walters AL Thompson KJ Kuwada TS Martinie JB Iannitti DA Gersin KS Sindram D Does a calculated "NAFLD fibrosis score" reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes Surg 2014 24 15 21 23934335
  75. [92]Naveau S Lamouri K Pourcher G Njiké-Nakseu M Ferretti S Courie R Tranchart H Ghinoiu M Balian A Prévot S Perlemuter G Dagher I The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD Obes Surg 2014 24 1693 1701 24841950
  76. [93]Fjeldborg K Pedersen SB Møller HJ Richelsen B Reduction in serum fibroblast growth factor-21 after gastric bypass is related to changes in hepatic fat content Surg Obes Relat Dis 2017 13 1515 1523 28552744
  77. [94]Hedderich DM Hasenberg T Haneder S Schoenberg SO Kücükoglu Ö Canbay A Otto M Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease: Magnetic Resonance Imaging Is an Effective, Non-invasive Method to Evaluate Changes in the Liver Fat Fraction Obes Surg 2017 27 1755 1762 28064372
  78. [95]Jiménez-Agüero R Emparanza JI Beguiristain A Bujanda L Alustiza JM García E Hijona E Gallego L Sánchez-González J Perugorria MJ Asensio JI Larburu S Garmendia M Larzabal M Portillo MP Aguirre L Banales JM Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery BMC Med 2014 12 137 25164060 PMC4145227
  79. [96]Ruiz-Tovar J Alsina ME Alpera MR OBELCHE Group Improvement of nonalcoholic fatty liver disease in morbidly obese patients after sleeve gastrectomy: association of ultrasonographic findings with lipid profile and liver enzymes Acta Chir Belg 2017 117 363 369 28585487
  80. [98]Giannetti M Piaggi P Ceccarini G Mazzeo S Querci G Fierabracci P Salvetti G Galli G Ricco I Martinelli S Di Salvo C Anselmino M Landi A Vitti P Pinchera A Santini F Hepatic left lobe volume is a sensitive index of metabolic improvement in obese women after gastric banding Int J Obes (Lond) 2012 36 336 341 22143620
  81. [99]Major P Pędziwiatr M Rubinkiewicz M Stanek M Głuszewska A Pisarska M Małczak P Budzyński A Budzyński P Impact of bariatric surgery on non-alcoholic fatty liver disease Pol Przegl Chir 2017 89 1 4 28537562
  82. [100]Winder JS Dudeck BS Schock S Lyn-Sue JR Haluck RS Rogers AM Radiographic Improvement of Hepatic Steatosis After Laparoscopic Roux-en-Y Gastric Bypass Obes Surg 2017 27 376 380 27440167
  83. [101]Alizai PH Wendl J Roeth AA Klink CD Luedde T Steinhoff I Neumann UP Schmeding M Ulmer F Functional Liver Recovery After Bariatric Surgery--a Prospective Cohort Study with the LiMAx Test Obes Surg 2015 25 2047 2053 25869925
  84. [102]Gribsholt SB Thomsen RW Svensson E Richelsen B Overall and cause-specific mortality after Roux-en-Y gastric bypass surgery: A nationwide cohort study Surg Obes Relat Dis 2017 13 581 587 27876334
  85. [103]Goossens N Hoshida Y Song WM Jung M Morel P Nakagawa S Zhang B Frossard JL Spahr L Friedman SL Negro F Rubbia-Brandt L Giostra E Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery Clin Gastroenterol Hepatol 2016 14 1619 1628 26492845 PMC4838546
  86. [104]Rebibo L Gerin O Verhaeghe P Dhahri A Cosse C Regimbeau JM Laparoscopic sleeve gastrectomy in patients with NASH-related cirrhosis: a case-matched study Surg Obes Relat Dis 2014 10 405 10; quiz 565 24355322

Cited by

Sorted by citations

Authors
Laursen, T. L., Hagemann, C. A., Wei, C., Kazankov, K., Thomsen, K. L., Knop, F. K., & Grønbæk, H.
Affiliations
  • Aarhus University Hospital (DK)
  • Gubra (Denmark) (DK)
  • Gentofte Hospital (DK)
ORCID
Venue
World Journal of Hepatology
Publisher
Baishideng Publishing Group Inc.
Published
2019-02-27
Volume
11
Issue
2
Pages
138-149
ISSN
1948-5182 (ISSN-L)
DOI
10.4254/wjh.v11.i2.138
PMC
PMC6393715
OpenAlex
W2916828510
Cited by
176
References
18
Citations by year
2026: 11 · 2025: 16 · 2024: 20 · 2023: 18 · 2022: 24 · 2021: 43 · 2020: 33 · 2019: 11
FWCI
4.05
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • World Journal of Hepatology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Amgen
  • Eli Lilly and Company
  • AstraZeneca
  • Sanofi
  • Steno Diabetes Center Copenhagen (SDCC 3.F CMP)
  • Novo Nordisk
  • Novo Nordisk Fonden (NNF10OC1013267, NNF11OC1014545, NNF14OC0012141)
  • Ipsen
  • Norgine
  • Sanming Project of Medicine in Shenzhen (SZSM201612074)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
bariatric surgery, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, obesity, metabolic syndrome, type 2 diabetes, glucagon-like peptide-1, gastrointestinal hormones, liver fibrosis, liver histopathology, weight loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review